Skip to main content
Premium Trial:

Request an Annual Quote

GenMark to Net $39.3M from Public Offering

NEW YORK (GenomeWeb News) – GenMark Diagnostics late on Wednesday priced its public offering of 10 million shares at $4.20 per share.

The offering, which was announced on Tuesday, is expected to close on June 26. The firm expects to raise net proceeds of $39.3 million.

Those funds will go toward R&D work to expand the Carlsbad, Calif.-based molecular diagnostic firm's test menu and to further develop its NexGen System, a sample-to-answer platform. It will also be used to expand the company's US and global commercialization operations.

JP Morgan is the sole book-running manager on the offering. William Blair & Co. and Canaccord Genuity are co-managers. The underwriters have a 30-day option to purchase up to an additional 1.5 million shares to cover any over-allotments.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.